Research analysts at Maxim Group began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued to clients and investors on Wednesday, June 26th, MarketBeat reports. The firm set a “buy” rating and a $4.00 price target on the specialty pharmaceutical company’s stock. Maxim Group’s price target points to a potential upside of 233.33% from the stock’s previous close.
Shares of NASDAQ:TTNP traded down $0.02 on Wednesday, reaching $1.20. The company had a trading volume of 129,334 shares, compared to its average volume of 742,614. Titan Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $5.94. The business has a 50 day moving average of $1.31. The firm has a market capitalization of $16.38 million, a price-to-earnings ratio of -1.52 and a beta of 1.00. The company has a quick ratio of 1.86, a current ratio of 2.12 and a debt-to-equity ratio of 1.18.
Titan Pharmaceuticals (NASDAQ:TTNP) last announced its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.08). The business had revenue of $0.95 million for the quarter. Titan Pharmaceuticals had a negative return on equity of 311.18% and a negative net margin of 168.23%. As a group, equities analysts expect that Titan Pharmaceuticals will post -0.68 EPS for the current year.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Featured Article: Dividend Yield
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.